Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 6,471 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 6,471 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $109,101.06. Following the completion of the sale, the insider now owns 54,322 shares in the company, valued at approximately $915,868.92. This trade represents a 10.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA opened at $17.84 on Friday. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm’s 50-day simple moving average is $16.74 and its 200 day simple moving average is $15.30. The firm has a market cap of $2.35 billion, a price-to-earnings ratio of -11.66 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of Centessa Pharmaceuticals in the third quarter worth $2,834,000. Wellington Management Group LLP bought a new stake in Centessa Pharmaceuticals during the third quarter worth about $1,609,000. State Street Corp acquired a new stake in Centessa Pharmaceuticals during the third quarter worth about $777,000. Ally Bridge Group NY LLC bought a new position in Centessa Pharmaceuticals in the 3rd quarter valued at about $4,951,000. Finally, GSA Capital Partners LLP raised its position in shares of Centessa Pharmaceuticals by 66.1% in the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after buying an additional 37,275 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CNTA shares. Guggenheim increased their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.